Send to

Choose Destination
Curr Opin Pharmacol. 2014 Oct;18:91-7. doi: 10.1016/j.coph.2014.09.008. Epub 2014 Sep 29.

Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?

Author information

Basilea Pharmaceutica International Ltd, Basel, Switzerland.
Indiana University, Simon Hall, 212 S. Hawthorne Drive, Bloomington, IN, USA. Electronic address:


Multidrug-resistant Gram-negative bacteria continue to pose a threat, with many infections caused by these pathogens being virtually untreatable. A number of new antibacterial agents are in late stage clinical development to treat these infections. Drugs in known classes such as new quinolones, aminoglycosides, tetracyclines, and β-lactams have been designed to evade many of the known resistance mechanisms, whereas newer drug classes include novel β-lactamase inhibitors in combination with new or approved β-lactams, and a peptidomimetic that have entered full clinical development. The establishment of public-private partnerships and an increase in pharmaceutical interest in antibacterial R&D are encouraging signs for the future.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center